复方皂矾丸辅助治疗耐多药肺结核的临床效果

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Compound Saponin Pills in the treatment of multidrug-resistant tuberculosis. Methods Forty patients with multidrug-resistant tuberculosis admitted to our hospital from June 2016 to December 2018 were selected as subjects. According to the random number table method, they were divided into experimental group and control group, 20 cases in each group. The two groups were used 3 to 5 sensitive anti-tuberculosis drugs according to the previous medication history and drug susceptibility test results. Conventional basic chemotherapy, the experimental group was added with Compound Saponin Pills orally on the original basis. The sputum negative conversion, chest X-ray lesion absorption, cavity closure rate and T cell subsets were observed after treatment in the two groups. Results There was no significant difference in the rate of sputum negative conversion between the two groups after 1, 2, 3, 4, 5, 6 months of treatment (P＞0.05), there was no significant difference in the total effective rate between the two groups after 6 months of treatment (P＞0.05), but serum CD4+, CD4+/CD8+ in the experimental group after treatment for 3 months and the cavity closure rate after treatment for 6 months were higher than those of the control group, and the CD8+ was lower than that of the control group. The differences were statistically significant (P＜0.05). Conclusion Compound Saponin Pills for the treatment of multidrug-resistant tuberculosis can increase the lung cavity absorption rate, significantly improve the cellular immune function and improve the prognosis of patients.

Key words： Compound Saponin Pills Multidrug-resistant tuberculosis Cellular immune function Tuberculosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I6/36

[1]	Edlin BR，Tokars JI，Grieco MH，et al.An outbreak of multidrugresistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome[J].N Engl J Med，1992，326（23）：1514-1521.
[2]	郑煦，代利霞.达那唑联合复方皂矾丸治疗再生障碍性贫血38 例[J].长江大学学报（自科版），2017，14（16）：33-35.
[3]	张稚淳，张晓波，丁皓，等.复方皂矾丸或联合西药治疗血液病疗效和安全性的Meta 分析[J].北京中医药大学学报，2018，41（10）：873-880.
[4]	王梅芳，陈杨，林花.复方皂矾丸联合环孢素A 及十一酸睾酮治疗非重型再生障碍性贫血疗效分析[J].中国药物与临床，2017，17（3）：396-397.
[5]	洪凤娟，王柳飞，韩明锦，等.乳腺癌化疗间歇期服用复方皂矾丸对贫血发生率的影响研究[J].中国现代药物应用，2017，11（15）：96-98.
[6]	朱丽，郑彤，梁香改，等.复方皂矾丸联合泼尼松治疗免疫性血小板减少症的疗效观察[J].甘肃医药，2017，36（1）：66-67.
[7]	Liu Z，Dong H，Wu B，et al.Is rifampin resistance a reliable predictive marker of multidrug -resistant tuberculosis in China：A meta-analysis of findings[J].J Infect，2019，79（4）：349-356.
[8]	CohnDL，BustreoF，RaviglioneMC.Drug-resistanttuberculosis：review of the worldwide situation and the WHO/IUATLD Global Surveillance Project.International Union Against Tuberculosis and Lung Disease[J].Clin Infect Dis，1997，24（Suppl 1）：S121-S130.
[9]	Sharma P，Lalwani J，Pandey P，et al.Factors associated with the development of secondary multidrug-resistant tuberculosis[J].Int J Prev Med，2019，10：67.
[10]	Aznar ML，Segura AR，Moreno MM，et al.Treatment outcomes and adverse events from a standardized multidrug-resistant tuberculosis regimen in a rural setting in angola[J].Am J Trop Med Hyg，2019，101（3）：502-509.
[11]	宋华峰，袁丹丹，陈慧，等.耐多药肺结核患者外周血中淋巴细胞比例变化分析[J].临床肺科杂志，2018，23（3）：391-395.
[13]	初乃惠，罗永艾，朱莉贞，等.化疗加免疫长疗程方案治疗耐多药结核病的随机对照研究[J].中国防痨杂志，2009，31（1）：10-14.
[14]	胡丽娜.γ-干扰素辅助治疗对耐多药肺结核患者免疫功能及痰菌转阴率的影响[J].临床研究，2019，27（5）：60-62.
[12]	Hartmann P，Plum G.Immunological defense mechanisms in tuberculosis and MAC-infection[J].Diagn Microbiol Infect Dis，1999，34（2）：147-152.
[15]	凌应冰，谢鸿恩，卢艳春.莫西沙星联合微卡治疗复治耐多药肺结核患者的临床疗效及免疫功能观察[J].中国实用医药，2017，12（5）：133-135.
[16]	邓彬，刘海燕，孙纪英，等.胸腺肽联合吡嗪酰胺治疗耐多药肺结核的近、中期疗效及对免疫功能的影响[J].检验医学与临床，2018，15（2）：209-212.
[17]	杜德兵，罗世珍，李达兵.血清sIL-2R 水平对MDR-TB的临床意义及IL-2 治疗的研究[J].传染病信息，2004，17（3）：119.